A $385 million settlement will resolve claims stemming from Abbott Laboratories' Sturgis, Michigan, baby formula plant, whose 2022 shutdown amid contamination concerns helped set off a nationwide shortage that put heavy pressure on families.
Here's what to know
According to The Associated Press, at the center of the dispute was Abbott's Sturgis facility, the largest baby formula plant in the United States. Abbott said the agreement covers claims involving a U.S. Department of Justice investigation and lawsuit, along with lawsuits from certain relators and claims by several state attorneys general.
The 2022 recall involved powdered infant formula sold under brands including Similac after problems emerged at the Michigan plant. Because the factory was such a major part of the U.S. supply, its shutdown worsened shortages on store shelves already strained by pandemic-related disruptions and stockpiling.
Abbott said the settlement "does not represent any finding of fault or liability." The company added that government regulators did not find Cronobacter sakazakii in unopened formula collected from the homes of the infants under investigation, and the bacterium can make infants seriously ill.
More background
According to The Associated Press, the Food and Drug Administration's investigation was followed by Abbott's closure of the Sturgis plant in February 2022. The facility was operating again by June 2022, though the hit to formula supply had already become a national crisis.
Abbott also said the Justice Department closed its criminal investigation during President Donald Trump's administration. Separately, the company said no unopened Abbott infant formula distributed to consumers has ever tested positive for Cronobacter sakazakii.
TCD Picks » Quince Spotlight
💡These best-sellers from Quince deliver affordable, sustainable luxury for all
To respond to the 2022 shortage, the Biden administration used emergency measures intended to restore formula availability. As reported by The Associated Press, that included relying on emergency federal powers to increase U.S. production, relaxing import rules for overseas manufacturers, and flying formula in from Europe.
Those actions were intended to help families regain access to formula as domestic manufacturing recovered.
Where can I learn more?
The Abbott formula crisis also fits into a bigger pattern: When major household brands come under scrutiny, families and regulators start looking more closely at product claims, packaging, and company decisions. These articles explore that same pressure around trust and accountability.
• On Amazon, shoppers accused Fisher-Price of mysterious reduced-packaging upcharges, making baby-product choices even murkier.
• Across consumer brands, experts showed how easy it is for companies to blur the truth on labels.
• At Target, shoppers learned to spot greenwashing in everyday products hidden behind familiar marketing cues.
Get TCD's free newsletters for easy tips, smart advice, and a chance to earn $5,000 toward home upgrades. To see more stories like this one, change your Google preferences here.
